This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2022 Feb 24;139(8):1124-1126.

doi: 10.1182/blood.2021013788.

A BAX door to venetoclax resistance

Franco Izzo^{1

2}, Dan A Landau^{1

2}

Affiliations

PMID: 35201333
DOI: 10.1182/blood.2021013788

Free article

Editorial

A BAX door to venetoclax resistance

Franco Izzo et al. Blood. 2022.

Free article

. 2022 Feb 24;139(8):1124-1126.

doi: 10.1182/blood.2021013788.

Authors

Franco Izzo^{1

2}, Dan A Landau^{1

2}

Affiliations

¹ New York Genome Center and.
² Weill Cornell Medicine.

PMID: 35201333
DOI: 10.1182/blood.2021013788

No abstract available

PubMed Disclaimer

Comment on

Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.
Blombery P, Lew TE, Dengler MA, Thompson ER, Lin VS, Chen X, Nguyen T, Panigrahi A, Handunnetti SM, Carney DA, Westerman DA, Tam CS, Adams JM, Wei AH, Huang DCS, Seymour JF, Roberts AW, Anderson MA. Blombery P, et al. Blood. 2022 Feb 24;139(8):1198-1207. doi: 10.1182/blood.2021012775. Blood. 2022. PMID: 34469514 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Silverchair Information Systems
Research Materials
- NCI CPTC Antibody Characterization Program